AVITA Medical, Inc. (RCEL)
NASDAQ: RCEL · Real-Time Price · USD
15.56
+0.34 (2.23%)
Nov 17, 2026, 2:11 PM EST - Market open
← View all transcripts

Investor update

Nov 11, 2026

Summary

Q3 revenue was $26.1m and FY26 guidance rose to $92m-$94m, with Q4 cash flow breakeven reaffirmed. Management cited margin gains, broader product adoption and reimbursement changes supporting growth.

Rudi Michelson
Investor Relations Executive, Monsoon Communications

Good morning, and thank you for joining this AVITA Medical quarterly Australian webinar. I'm Rudi Michelson of Monsoon Communications. The AVITA team, CEO Cary Vance, CFO David O'Toole, and Ben Atkins, VP Investor Relations and Corporate Communications, are in Australia for a Sydney-Melbourne roadshow this week, and this webinar has been arranged so everyone has a chance to be briefed direct and ask questions on AVITA's progress. You can submit questions using the Q&A function, and we'll try to get to them after the presentation. I'll now hand over to Cary Vance to begin the presentation.

Cary Vance
CEO, AVITA Medical

Thank you, Rudi. It's good to be with all of you again. Appreciate your time today. Look forward to updating you on the company. We've been working hard. We've made some progress. I want to harken back to a year ago when I was a few weeks into the job. I came to Australia in November, and we did this webinar and tried to explain where I thought the company was at. I committed to digging in, drilling in commercially and operationally to the business to understand how we can make the improvements that are needed and were needed, and I think we did that. I think in Q4 last year, we stabilized the business. I think we really started to understand the market, our products, how they can impact patients, and how we can create leverage in the marketplace to grow.

We went on then to make some commitments for 2026 in terms of guidance and committed to growing every quarter, which we've done. Then as we went along throughout the year, and we've grown every quarter and had additional discipline around operations, around cash use, we increased our guidance after Q2. We increased our guidance again after Q3, and we reaffirmed our pledge at the end of Q2 to get to cash flow breakeven and generate cash in Q4. So, it's been a progressive year. A lot of good things happening both on the back end of the business and the front end. So, excited to give you an update of our Q3 numbers today. Again, as I just referenced, when I was here a year ago, we were talking about $17.1 million-$17.6 million as kind of a baseline of the business across our portfolio.

What we basically did is marched quarter over quarter this year to progressive growth, really across the product lines, even within RECELL across those product lines. Our manual system, as well as RECELL GO and RECELL GO mini, are all being utilized in a greater way, additional physicians using it, and then the physicians using it doing so with different types of procedures and different-size procedures. Along with that, as you might expect, we looked at cash use, and we generally have a Q1 set of one-time payments, and that's the $9.9 million there. But other than that, we marched towards cash flow breakeven, and we made a big jump in that regard to going from $3.2 million - $600,000 this past quarter. Again, we reaffirmed that we'll be cash flow breakeven and generate cash in Q4. We raised our guidance to $92 million - $94 million as well.

One thing I want to point out here, that we're really excited about the $26.1 million quarter, but if you look at those bars on that graph, it's not a particular straight line this year. There's, in a good way, I guess we had a real bump in Q3. My estimation, in speaking to our sales leaders and applying some analytics to it, I believe there's about $1 million of that is just a lot of patients. In the U.S., July and August were very hot months. People are out doing fireworks and barbecues, and it's just hot out there. It created a climate, unfortunately for them, with large wounds and several wounds in patients, and that impacted the revenue, I think, to a $1 million degree.

When you look at our guidance, $92 million-$94 million, it basically says, well, you're going to do between $24.9 million and $26.9 million. If you look at that upper end of the guidance and you say, "Well, are you saying you're only going to do $26.5 million or something like that at the best?" That's pretty flat to Q3. That's not so much a commentary on Q4 and being flat. It's more a commentary on Q3 being very robust. If you drew a line from $19.3 million - $21.7 million to, let's say, $25 million, and then to nearly $27 million, that's the kind of trajectory organically that the company is on right now that we can count on, and that we can count on going into 2027 as we start to look to continue to grow quarter-over-quarter throughout 2027.

That kind of seasonality in Q3, we pretty much have an N of one in terms of whether or not that's going to occur every summer in the U.S. We'll see what happens this summer, and as we go along this, we try to be very transparent about understanding our business and the tendencies that the market has in the U.S. so that you can track with that as we do. Again, we're growing across our product lines. In here, you might see a couple flatness, and I'll address that in a second. But really, RECELL quarter-over-quarter was 20% growth, as was Cohealyx. We're real happy with how that's growing. PermeaDerm flatness there, it's not real flatness. It's just that when a product line is so small that it only takes a couple orders to push into October to make it look flat.

I think you'll see us bounce back here in Q4 with some good growth in PermeaDerm. Same thing with international. Being so small, it doesn't take much to skew that a little bit. Feel really good across the product portfolio in the U.S. and internationally. On the right side, you just see a confirmation it's not just about revenue going up, but units being used from a volumetric standpoint. Just want to share that kind of data so that you see this isn't just a matter of us taking price or any other anomaly in terms of revenue going up, but it's true volume increase quarter-over-quarter. I'll hand it over to David to dive into the numbers a little bit more.

David O'Toole
CFO, AVITA Medical

Thanks, Cary, and good morning to everyone on the call. Appreciate you taking the time. I want to point out a few things on this slide that may not be apparent. For one, you can see that we're getting to a point where we're getting operating leverage. We had revenue increase of $4.4 million from Q2 of 2026 - Q3 of 2026, and our operating expenses stayed flat. We're generating more revenue, keeping our operating expenses at a constant level, and on top of that, we've increased our gross margin. Our gross margin for RECELL only is at 88.4% in Q3, and there was some dilution because, as everyone knows, we share the ASP, the average sales price, with our two partners for Cohealyx and PermeaDerm at around 50% each. There will continue to be some dilution as those products grow.

However, we think there's so much opportunity for RECELL at a higher margin that we don't see our gross profit margin going down below the 82%-83%, 84%. You can see that we increased that gross profit margin from Q2 of 2026 to Q3 of 2026 by 210 basis points. We did that through looking at some manufacturing inefficiencies. We took some costs out. We had been working through some obsolescence and reserves that we had in previous quarters. All of that's done. Again, we believe that our gross margin for RECELL will continue in the 85%-89%, and gross profit margin overall disclosed will be in the 82%-84%. Cary's talked about the use of cash going down. Our expectation is that we're going to cross over this quarter to cash flow break-even and start generating cash.

We do, as was pointed out earlier, and I'll just state it also, we do believe that in first quarter of 2027, we have these one-time payments that benefit reset. We have incentive compensation that we have to pay, bonuses, commissions, and also we've had this payment to Regenity, our partner for Cohealyx, on the books of $3 million that will need to be paid in January. So you will see a use of cash in the first quarter of 2027 again, and it won't be to the magnitude of the $9.9 million that we had this year, but it will be a use of cash, and then we expect every quarter thereafter to be generating cash. Our revenue will be such going out of 2027 that we should not see a use of cash in the first quarter of 2028 and going forward.

We believe that we will get to cash flow break-even this quarter, have use of cash next quarter, in first quarter of 2027, and then be generating cash thereafter. One last thing I want to talk about is we did draw down, we had this debt facility with Perceptive Advisors, and it was a total debt facility of $60 million. We had already drawn down $50, and the remaining $10 was only available if we had reached $85 million trailing 12 months revenue, and we did that this quarter, and we did that probably two quarters before even Perceptive thought we were going to do that, because that $85 million was available through March of 2027. So it was available. It was a short-term way to put cash on our balance sheet.

We now have pro forma of about $21 million of cash. It also allowed us, and this is probably just a U.S. concept, but in our financial reporting to the SEC, we had previous quarters had a qualification around substantial doubt about our ability to continue as a going concern. We were able to alleviate that qualification, and that will no longer be in our financial reporting going forward. Next slide.

Cary Vance
CEO, AVITA Medical

Let me just jump in if I could, David, to talk about operating expense, because over the last few days in meetings, we have been asked about our ability to keep this relatively flat over the next one, two, three years. I think some of you have been in with AVITA for a while, and when I took over last November again, or last October, one of the complaints that I had heard is how much money we spend, right? Some of that was getting a handle on some of our operational expenses, and that is David and his team and everybody at the company did a great job of that.

One of the things was when we were in the $50 million- $60 million-$70 million range every year, the number of reps that we had in the field and the amount of revenue per rep, and there was, I think, some criticism of, are you getting the ROI for that kind of investment? One of the things I looked at is that a place where we could take out? Could we trim the number of reps and the cost for sales and marketing? What I concluded is that we were poised to grow, and that the investment that had been made and the relationships and some of the groundwork that was done around RECELL and again, PermeaDerm and Cohealyx as well, was going to start to pay off.

I would much rather get operating leverage from our sales reps than start cutting to just save money, because we are a growth company. I think what you see is maybe two years ago, maybe we had more reps than we needed per the revenue that we were bringing in. But next year, the year after, and the year after, we really shouldn't have to add reps. Maybe one or two here or there where there are gaps, but we really should be able to handle much more revenue given the existing reps. If you can imagine, for a rep that covers an account and a physician, how much more work is it for them if they use Cohealyx and RECELL on that patient, for example, or if they use RECELL more often? It is really not a game-changer in terms of rising operating expenses with rising revenues.

I just wanted to point that out because I know we've been asked about that quite a bit the last few days.

Rudi Michelson
Investor Relations Executive, Monsoon Communications

Thank you.

David O'Toole
CFO, AVITA Medical

Just a quick comment on this slide, and then you can take it back, Cary. You can see on the right the growth that we've had over the last five years. There was a dip. We knew that. In 2025, we only grew 11%. But we are projecting at the midpoint of our new guidance of $92 million-$94 million that we will grow 30% over 2025. That's going to be a fabulous result. However, going forward, we don't think that that's going to continue at a 30% rate. I hope it does, but at the same time, our operating plans will be more around growing at the 20%-25% in subsequent years. That's what we're trying to achieve there.

I'll restate that we have raised guidance for this second consecutive time, going from $86 million-$89 million, which we raised last quarter, going to $92 million-$94 million, and the midpoint being that $93 million number for the year. Cary, back to you.

Cary Vance
CEO, AVITA Medical

Thanks, David. A couple things that I'm comfortable with, and that is anybody on this call going back to the transcripts from the last three, four times that we did this call and looking at what we said. I'm also comfortable with saying some things here today that you can look to in the quarters ahead, because I think what we're trying to do is understand our business and then share it with you real-time in a transparent way. It might not be that everything is perfect, but again, if something happens different than what we think is going to happen, our job is to explain it and to help you understand how we're going to mitigate something or move on and improve it. I used the term headwinds quite a bit a year ago because we had a handful of them. One of them was reimbursement.

The other was, we had a CEO change. We had a change in some of the makeup of our salespeople. As I described those things as headwinds, what I also said is those things, when we fix them or as they evolve, that they will become tailwinds. This is an example of that. If you remember, we talked about how CMS delegated reimbursement to the seven MACs, the Medicare Administrative Contractors. Then the MACs didn't publish the rates. I think two or three of them did it last summer, then a couple more in the fall, and then one or two more in January, February of this year. So, that was a task for us to get them all on board. A lot of lobbying and pushing to get them to do that, but we solved it.

But we always knew that that was a bridge to a better place, and we're at that better place. We've been able to take advantage of that system this year with the MACs, obviously, with the growth that we've had. But this is better, and it is permanent, and it will be consistent. The thing you want to know about this, because we can dive into the details, but the physicians are the ones that pushed for this coding. Not just the amounts, but the types of reimbursement that made sense for how they practice every day. Not only were they involved in doing it, not only was the American Burn Association involved, but they're all really happy and excited about it.

Beyond happy and excited, which is great when you're talking about money in their pocket and getting reimbursed, is a comfort level that this is here to stay, this is consistent, easy to understand, and something that they can count on. If you can imagine, if you go to an American Burn Association conference this past year in Orlando, you have multiple physicians talking about different MACs that either have or have not published. For the most part, they're reimbursing the same, but they're not speaking in common language. This kind of unifies that group, so they're having common conversations at regional meetings about what this means for their practice, and people that are not on board with doing a RECELL-type procedure are getting on board because they understand it now. They know they can count on it.

It just goes from eight family codes to four. An example of that is bundling together the harvest step, the preparation step, and the application step into one code. It levels out between manual and automated RECELL products. It enhances and clarifies payment associated with outpatient centers or ambulatory surgical centers. As you probably all know, there are a good amount of procedures that start moving out to those centers from out of the hospital. Then just a little thing, bottom right corner there. In the past, what they've done is when you have a wound on a pediatric, say you have a three-year-old child that has dumped boiling water on themselves accidentally, and they have a wound that's this big, and it's on their stomach, and that's not that big of a wound, really.

They would measure it in centimeters square, and they would get paid in that way. But this code changes it to the percent total body surface area, which is actually a lot bigger and a lot bigger deal, because it gets physicians to use the RECELL technology in terms of scarring, pigmentation, and recovery and healing. As you all know, a three-year-old boy becomes a 23-year-old man, and that small wound becomes very big, and they need that. They're going to have that for the rest of their lives. So again, just encourages the right behavior financially and with clarity for the billing departments of the hospital. So really, a positive here in the next kind of six weeks. This all goes into practice, and it'll just help us going forward for years. This is a reminder of our portfolio.

You're all familiar with PermeaDerm, Cohealyx, and RECELL, but if you look at from when a patient comes in to when a patient leaves, we talk about the efficiency of our salespeople, but we also talk about opportunity, revenue opportunity, and the opportunity to help patients in different parts of that process, that continuum of care. Essentially, PermeaDerm is a temporizer that they can use to protect the wound, to analyze and watch the wound as they can see into the wound bed for a period of days until they figure out what they're going to do, see how the patient is doing, and so on. Then, depending on the depth of the wound, they'll use Cohealyx to build up the wound bed, vascularize the wound bed, prepare it for grafting. Now, and then obviously RECELL, either used to spray by itself or with a mesh skin graft.

The commonality across these products is time and money, and obviously clinical effectiveness, but time and money. So PermeaDerm is about a third of the price of allograft, which is conventionally used across hospitals in the U.S. A third of the price, easier to use. With allografts or cadaver skin, you have to freeze it, buy it, track it, and this is much easier to prepare. You stick it on the shelf, it's ready to go. It's also transparent, which, by the way, I describe them assessing the wound. Isn't transparency important when you're trying to see the wound? Allograft is opaque and difficult to see and difficult to use. Cohealyx, you've heard the Cohealyx-1 data that was brought out in April from physicians where we, on average, were 13 days to wound bed readiness for grafting, whereas the competition was an average of 33 days.

That difference of 20 days is very meaningful, not just for the patient, that is fewer dressing changes, more chance for infection, less pain, but also for the hospital who cares for patients every day in the acute setting. You might imagine that where they have staff shortages and where it costs a lot of money to take care of patients in the acute setting, the sooner they can get out, the better for them, their families, and for the hospital. RECELL, just reminding you that 36% reduction in length of stay in using RECELL versus conventional skin grafting. Again, better healing, but also faster healing that allows for the economics of the hospital to improve. I will say that you can look next week for part two of the Cohealyx-1 study, which will focus more on the durability of the matrix, right?

You marry up the speed at which it prepares the wound bed with this second set of data that shows the durability, six-month follow-up. What we will do is we will then put part one, part two, put it together, we will submit it for publication by the end of the year for next year. PermeaDerm, the PermeaDerm I study has been submitted. The expectation is that it will publish here in the early parts of 2027. The point over on the right that is important because there is a lot commercially, it is really important to have the right kind of peer pressure and education and understanding with clinicians.

What we are seeing over the past couple months at regional burn conferences and what we will see in the months ahead is several dozens of podium presentations and presentations involving one or two or all three of our products from independent clinicians.

We have as many presentations going on as all of our competition combined. Extremely exciting not only to show the data, but to have an impact on clinicians that attend those conferences and are impacted by the work of their colleagues. This is the PermeaDerm study, again, just showing comparability with AlloDerm, which is important from a clinical standpoint. I talked to you about some of the usability issues that we have an advantage. But really, at some point, it becomes fairly simple when you are a third of the price. That is what this signifies as well, in terms of workflow, in terms of price, in terms of ease of use. So, it is, again, extremely powerful data coming out that is real world.

Again, across the continuum, I just kind of mentioned this, where each of the studies, RECELL, Cohealyx, PermeaDerm, involve time, they involve money, they involve clinical effectiveness. That is what you need when you have a portfolio out there every day. So, I am glad we invested the dollars and the time and the focus on clinical studies that make sense, that have a real impact, and have a return on those investments. I think as some of these start to wrap up, which, with you as investors and what we as a company plan to do is invest in clinical studies that move the needle in a fairly short fashion, very cost-efficient fashion, like we have done here over the last couple years, and that we reap the benefits of that right now commercially in the months and quarters ahead.

This is just a photo, aside from just generally the progress that we're making in Japan, really solid business in Japan. In Europe, we launched at the beginning of this year. I think most of you, again, in February or January or February, heard about the Swiss Nightclub fire. That really highlighted the fact that we weren't in Europe yet, or we weren't there more than a handful of weeks. Since then, we've continued to make progress in U.K., in Germany, in a handful of countries. So we're excited about what we're doing there. Some of you also may have heard about the Canadian explosion fire where dozens of servicemen were injured. A handful of them lost their lives as well. We're not commercially available in Canada, but we did send RECELL kits up there. Basically, it's a very close community.

The Canadians, the President of the American Burn Association, texted me, and I texted our group, and we sent kits up there, and we sent a couple people up there to help those victims. In Australia, right, where this whole thing started with that kind of an event, where people came to Perth and were treated by Dr. Wood, we're starting to make some good headway on the eastern side of the country. This is just a few pictures of Dr. Kimble in Brisbane doing some really good work with RECELL. We're proud of the fact that not only we have great investors here in Australia, but really some uptake in terms of our commercial progress and clinical progress here in Australia. Just in summary, I think this is a fairly straightforward business.

I think people are excited and even relieved at the kind of progress that we've made. But frankly, we're just getting started. This is year one. We've tried to make a lot of changes while we're trying to grow. What I feel really excited about in 2027 is that there's a lot of those things that we won't have to do, where we can really focus. We won't have to focus on trying to get people to understand reimbursement. We won't have to have new reps and some turnover and a different compensation plan for our reps and so on. We move seamlessly, for the most part, into 2027, just focused on our customers, focused on driving growth across the portfolio.

I think right now we have about 25 accounts that are using all three of our products to some degree, and about 70 - 75 of them use two of them. So RECELL plus Cohealyx, RECELL plus PermeaDerm. We're making progress not just in each product in our portfolio, but across the portfolio. In some ways, economically and clinically, there's a synergistic effect for them. If that's the case where they're finding value, we're going to continue to gain share and penetration. So we look forward to that in the coming quarters. With that, I'll hand it over for questions.

Rudi Michelson
Investor Relations Executive, Monsoon Communications

Thank you, Cary. We'll now move on to investor questions. If you have any questions, you can continue to submit them using the Q&A function. I'll now hand over to Ben Atkins to run the Q&A.

Ben Atkins
VP of Investor Relations and Corporate Communications, AVITA Medical

Thanks, Rudi, and good morning to everybody in Australia. For those calling in from the U.S., hello to you too. I have a number of questions here, and I will go through them, and I'll put these first questions to you, Cary, and then we'll have a couple for you, David, on the finances. Cary, starting, I guess, with market opportunity and how we see penetration, can you perhaps talk a little bit about the $1.3 billion TAM in the 200 focused accounts and sort of how you see that breaking down? At the sort of procedural level between burns, trauma, and surgical repair, can you perhaps just talk a little bit about where you see kind of penetration at the sort of grafting level?

Cary Vance
CEO, AVITA Medical

Sure. Okay, thank you. We're at about $600 million-$650 million in RECELL TAM opportunity, about $450 million in Cohealyx, about $200 million-$250 million in PermeaDerm. That's the opportunity out there. Obviously, we've just scratched the surface in Cohealyx and PermeaDerm. I mean, you can see the growth, but those are still relatively small numbers. We look forward to taking more than our fair share of that piece of the pie in the dermal matrix space and in the temporizer space. Obviously, RECELL, we see ourselves as very under-penetrated still, even in the burn space, which we've got some history there. I think when you talk about burn and trauma and surgical wounds, we're used to burn. I think they're larger wounds. RECELL was made for those kinds of wounds.

The same concept of healing and reduction of scarring and all the reasons why you'd use RECELL on a burn wound, when you look at a smaller, more complex wound that can come from trauma or from surgical site, the same concept resonates. What we do is, when people think about using it on a smaller wound that maybe aren't used to RECELL, we make the same arguments that we make all the time, and that is, there's an economic argument to it in terms of efficiency, and it's better for your patient, better healing, less scarring, all of that. They can get out of the hospital sooner, and it saves the hospital money. There's a reimbursement component to it, as we said here.

And then just educating them on the clinical side of it and making them feel comfortable just changing the way they practice medicine. I think that that is a kind of a constant effort from our salespeople. We do not just dump the dump truck of data on physicians. We try to drill down as to why they would not use it, why they would not use it more often on these wounds when they use them on these wounds, and we address that resistance through education, through, for example, RECELL GO mini, which is a smaller version of RECELL GO with a smaller cup, a lower price for that smaller wound, addresses it from a technological standpoint.

Again, we marry that up with clinical data, we marry that up with real-world peer integration, workflow data, economic data, and that is how you move the needle in these other markets like trauma and surgical wounds.

That will be part of the growth process in the coming quarters.

Ben Atkins
VP of Investor Relations and Corporate Communications, AVITA Medical

Cary, I think you, in your answer there, addressed my next question, which was going to be related to kind of what we see as some of the barriers to U.S. surgeons adopting RECELL over their more preferred sort of historic ways of just skin grafting. But sort of related to that, maybe looking beyond the U.S. internationally, what do you see as some of the sort of near-term challenges and opportunities in the international markets as we continue to engage the burn community there?

Cary Vance
CEO, AVITA Medical

Yeah, I think it is, first of all, it is important for us to understand, we use the word international like one word. Every country is different, and within every country, every physician is different. Every hospital, what challenges they have. A hospital that has economic challenges may be more receptive to an economic argument for switching how they practice medicine. What we are trying not to do is be lazy and just say, "Well, internationally," or, "We are just going to address all of these issues and tell them all the reasons why they should use it." What we do is we find out, I know it seems like a simple concept, but this physician, why are they not using it? Or if they use it here, why do not they use it there?

Even if they say, if they were to make a comment like, "Well, I just don't think it's worth it." What does that mean? Does that mean they don't believe the science? Does that mean they don't really, they think it takes too much time? Do they think it's too complicated, that it costs too much? What does that mean?

That is why we have salespeople who are really good at drilling down into why people do or do not use a product to make sure that our job is to arm them with data, with references that they can incorporate, best practices that other people that want to use it, but they are not comfortable with it and need to be educated, or they need to know how Dr. So-and-so in one state over uses it, so he puts it in the RECELL GO device, and while it's disaggregating the skin cells, they do something else. It is just all of that where our sales reps are getting really good and our sales leadership's getting really good at not only aggregating their data, but drilling in kind of territory by territory, physician by physician, so that it's very targeted. We know where the potential is.

We know how to address that potential. Again, just early days on a lot of opportunity, and that goes for international. Our distributors in Australia have different economics than they do in Japan, so they address those, and we give them the data they need to address those.

Ben Atkins
VP of Investor Relations and Corporate Communications, AVITA Medical

Staying with RECELL for just a moment, a more specific question. We see RECELL had benefited from NTAP this past year to provide a little incentive to hospitals to adopt Mini. That ends at the end of September. What impact, if any, do you see with that ending?

Cary Vance
CEO, AVITA Medical

Yeah, for better or worse, with everything that's gone well this year in terms of growth, NTAP didn't have much of an impact at all. Even though we had that and maybe say, "Well, that didn't have much impact," that's bad news. Well, the other news is that it expired, and it's not going to have any impact. Because it was a nice-to-have. For a lot of companies, when they have NTAP, they really need it, and they really make the most of it. For us, I think we had a lot of other factors, a lot of other data, and that's what we used more than anything to move the needle in RECELL GO Mini and our other products. So, that going away is not going to impact us at all.

Ben Atkins
VP of Investor Relations and Corporate Communications, AVITA Medical

Okay, I'll let you take a breath for a moment. David, I'll turn this next question to you.

David O'Toole
CFO, AVITA Medical

Sure.

Ben Atkins
VP of Investor Relations and Corporate Communications, AVITA Medical

With 25% long-term growth and breakeven this quarter, will 2027 operating expenses stay close to the current $24.6 million per quarter, or do you see that stepping up with sales hiring? Then part two of the question, when do you expect GAAP profitability?

David O'Toole
CFO, AVITA Medical

Yeah. Thanks, Ben. So, we discussed our operating expenses to some degree already. We expect that our operating expense lines will stay relatively flat to where they are right now. Will they creep up, for example, because of stock-based compensation, which is a non-cash item? The answer may be yes. We still look for ways to decrease our overall operating expenses. Sales and marketing may go up by the one or two new salespeople that we add. But overall, to answer the question, we expect our operating expenses to stay in line with a little bit of an increase for the foreseeable future. Your second part of the question, when do we expect to have GAAP profitability? We're not giving guidance on that right now.

We are heading in that direction, and when we have clear sight on when that's going to happen, we will be sharing that with all of our investors.

Ben Atkins
VP of Investor Relations and Corporate Communications, AVITA Medical

David, this next question, again, I think is really for you. Can you share the strategy for the repayment of the $60 million credit facility?

David O'Toole
CFO, AVITA Medical

Yeah. At this point in time, it is a five-year term. We are one year into it. It is a balloon payment at the end of the term, and we can prepay it. We can prepay part of it. There is a penalty, I would say a payment penalty that is attributed to making payments on the loan. At this point in time, we are looking at just getting to cash flow breakeven, generating cash, and if we still have the loan in four years, we will have more than enough cash to pay back the loan in that timeframe.

Ben Atkins
VP of Investor Relations and Corporate Communications, AVITA Medical

Thanks, David. Another question, which I think I can address, but it relates to kind of our clinical data and our studies, and I have a question on sort of the future of our R&D spend, which I will come to in a minute and put that to Cary, you and to you, David. Let me just this question. Will you make an announcement when the Cohealyx-1 six-month results are in, or wait until the fourth quarter earnings call? Thank you. To answer that question, we will be. As you know, we announced the interim data back in April, which was the primary endpoint, which was the time to graft readiness. This next set of data will build on that with six-month data post-grafting.

That will be shared within the next week or two on podium in the U.S. from one of the leading investigators, and we will be press releasing that also. Please watch this space. Sort of keeping with that theme on clinical studies, Cary, you covered the sort of key studies that we've been looking at this past year and how they're going to support us next year. But looking a little bit ahead, should we expect R&D expenses now to reduce? Will they be replaced, or will they be replaced with new activities, such as a Cohealyx-2 or a PermeaDerm-2? If we are going to be doing some new R&D, what might that look like?

Cary Vance
CEO, AVITA Medical

R&D expenses include regulatory quality, clinical studies, and then obviously research, product development, and so on. I don't think it's a surprise to anybody. We have three product lines. They're either fairly new. I mean, even if you look at RECELL GO, still fairly new. RECELL GO mini, fairly new, very under-penetrated. You have PermeaDerm and Cohealyx, again, very new in the bag. If you were us, what would you do? We're growing, and we're fine, and we have a lot of room to grow, and we expect to grow over the next number of years. It'd be simple and easy to not spend any money and rest on our laurels and just sell what we've got. Or you could invest in studies and data, real-world data, post-market, that bolsters your position in the marketplace around the clinical effectiveness or the economics around your products.

Or you could say, "Well, we'd rather disrupt ourselves at some point." RECELL is one of one. They have really strong IP. They have really strong kind of economic advantage in the marketplace. But at some point, is there somebody that could come up with something? We want that to be us. What we're doing is we're collaborating, we're researching, we're looking for new and better ways in years out to utilize RECELL and that technology in better ways. We do that. We look at potential other technologies that could fit our portfolio potentially without getting distracted. We look at RECELL GO and are there ways and the mechanism of action where you could make it smaller, faster, cheaper, take some cost out, better, easier to use.

We do all that, and that's what every company does, kind of next-gen products, clinical studies that have a quick ROI and you can use this leverage in the marketplace. We're going to do all of that, but we're going to be careful with what we spend, and we're only going to invest those dollars into things that get us a strong return, and we're going to do it very strategically. Again, that's kind of a longer answer to it, but I think people that are used to the company kind of doing a lot of R&D work and getting a lot of regulatory approval and then doing these quick studies over the last year and a half or two, I think there could be a tendency either internally or externally to say, "Okay, you guys are good now. Stop spending R&D dollars.

Stop looking into clinical studies." I think we're very careful with the funds, very strategic about it, but there's definitely some things we can do to accelerate what we're doing in the years out.

Ben Atkins
VP of Investor Relations and Corporate Communications, AVITA Medical

Thanks, Cary. David, Cary, I think between your remarks and the questions you've just answered, I think one question just came in, so thank you. With Dr. Fiona Wood, do you see further future collaboration with Dr. Fiona Wood on any developments?

Cary Vance
CEO, AVITA Medical

Yeah. I mean, we support her foundation. We collaborate with her. We talk to her, keep in touch with her on a regular basis, and as we do with other people. The quick answer is yes. Yes, Dr. Wood, as well as a number of other innovative people in the world, we're always looking for ways to collaborate where it makes sense.

Ben Atkins
VP of Investor Relations and Corporate Communications, AVITA Medical

I would say, from your end too, Dr. Wood has been receiving a number of accolades, well-deserved accolades this year, which I think is a great tribute to her work and also the value that RECELL brings to the community. So, a win on both fronts. Well, David, Cary, I think you've addressed all of the questions and all of the topics that were raised in advance through your remarks in Q&A. So, Cary, I will just sort of hand to you to say any closing remarks before we close the call.

Cary Vance
CEO, AVITA Medical

Yeah. I mean, I just want to say thank you. I mean, I think that it's been a gratifying year to make progress, but it's also been an immense amount of patience over the years, and even over the past year, to kind of take investors on the ride with us as we've tried to do that. We've tried to be transparent about the things, the challenges in front of us, and the things that we're trying to accomplish. Every quarter, when we accomplish some of those things, I'm happy to report back to you because we're accountable to you, not only the money that we spend, but the return on investment that we get from that. I look forward to continuing to do that in the next couple months and next quarter, and we expect to continue on this track going forward.

Again, thank you for your support and your time today.